ipilimumab,nivolumab
bms
[]
#gi23 [dr. ken kato]
checkmate 648 (29 mo f/u): nivo + chemo or nivo + ipi vs. chemo in 1l advanced esoph scc os benefit maintained for both nivo-containing arms benefit seen in all randomized pts (regardless of pdl1 status) 
Oncologist | Focus on #NETs | she/her 
Division Chief, GI Oncology @YaleCancer | Consultant Editor @JCO_ASCO |
Tweets mine | ASCO FCOI: https://t.co/UuqIAQ54sX